The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): Unblinded results from a randomized phase II study.
Brian I. Rini
Consultant or Advisory Role - Argos Therapeutics; AVEO; Bristol-Myers Squibb; GlaxoSmithKline; Pfizer; Roche
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Pfizer
Viktor Gruenwald
Consultant or Advisory Role - AVEO; AVEO; Bayer; GlaxoSmithKline; GlaxoSmithKline; Novartis; Novartis; Pfizer; Pfizer; Roche; Roche
Honoraria - Bayer; GlaxoSmithKline; GlaxoSmithKline; Novartis; Novartis; Pfizer; Pfizer; Roche
Mayer N. Fishman
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer
Bohuslav Melichar
No relevant relationships to disclose
Takeshi Ueda
Honoraria - Pfizer
A. H. Bair
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Ying Chen
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Paul W. Bycott
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Dmitri Pavlov
Employment or Leadership Position - Pfizer; Pfizer
Stock Ownership - Pfizer; Pfizer
Sinil Kim
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Eric Jonasch
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer